Tesla proposes to buy Solar City for $26.50-$28.50/share
•Solar City (NASDAQ:SCTY) +22.3% AH after Tesla (NASDAQ:TSLA) says in a blog post that it has made an offer to acquire the company; TSLA -10% AH.
•TSLA proposes an exchange ratio of 0.122x to 0.131x shares of Tesla common stock for each share of SCTY, which represents a value of $26.50-$28.50/share, or a 21% premium over today's closing price.
•TSLA says its proposal builds on a partnership between the two companies where SCTY uses TSLA battery packs as part of its solar projects.
So as TSLA shares fall so does SCTY buy out offer. This deal sucks!
Un-real & u idiots are buying into this BS? So now we have to wait for bankruptcy in May in stead of April. Oh well I can wait another month for this pos to go to ZERO!
The rules have two main parts, each of which could affect the Pfizer deal. First, the government would go after what it calls "serial inverters," large companies created through multiple inversions or takeovers of U.S. companies. The government would disregard U.S. assets acquired by such companies over the previous three years.
Consider Allergan. The company's current heft is the result of several cross-border deals, starting with the 2013 inversion of Actavis Inc., a small New Jersey-based drugmaker, through a takeover of Ireland-based Warner Chilcott PLC. What followed was a string of ever-larger deals, culminating in Actavis's $66 billion takeover of U.S.-based Allergan Inc. last year.
Under the new Treasury regulations, those deals would be disregarded for the purposes of determining Allergan's size under the tax law. The three-year window would cover the 2015 merger of Actavis and Allergan, Actavis' $25 billion purchase of Forest Laboratories Inc. in 2014, and the original $5 billion Warner Chilcott deal.
Stripping those deals out of Allergan's closing market capitalization of $106 billion could make it too small to serve as Pfizer's inversion partner under federal rules that disfavor lopsided mergers, or limit the financial benefits of the arrangement.
To reap the full benefits of inverting, the U.S. company's shareholders should own between 50% and 60% of the merged entity, which requires a partner of carefully calibrated size. Above that, some restrictions apply, including rules making it harder for companies to access foreign profits. The Pfizer-Allergan deal is structured so that Pfizer's shareholders will own 56% of the company.
Mr. Willens said the new percentage in the Pfizer-Allergan deal would be at least 60% and could approach 80%, above which all benefits of the inversion are lost.
"It certainly puts a crimp in the deal and it's not out of the question I suppose that Pfizer would want to rethink the transaction given the dev
That's a 14% increase! 34.5% of the float. All time high short interest, while the stock price is at a 2 year low. Not good! Look for AMAG to slide back down to $15 or less. If long, cut your loses & move on. Amag is a dog!
Deutsche analyst Nandan Amladi also cut his PT to $35 (from $50), saying that the slowdown in Verint's emerging market business and slower-than-expected enterprise growth will weigh on results going forward.
Credit Suisse analyst Michael Nemeroff, meanwhile, slashes his PT to $29 (from $45), arguing that Verint lacks near-term catalysts to drive the stock higher.
Treasury Secretary Jacob Lew said in a new statement. "This will have an important effect, but we cannot stop these transactions without new legislation. I urge Congress to move forward with anti-inversion legislation this year," Lew added.
IRS has no power to create new laws, congress must enact & pass new law. This is nothing more then political gesturing.
3/28/2016 Robert W. Baird Lower Price Target Outperform $26.00 - $25.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
3/28/2016 Leerink Swann Lower Price Target Outperform $25.00 - $23.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
3/28/2016 Ladenburg Thalmann Downgrade Buy - Neutral View Rating Details Tweet This Rating Share This Rating on StockTwits
3/28/2016 Jefferies Group Upgrade Underperform - Hold $16.00 - $19.00
Earning estimates must be falling like a cheap $10 #$%$. Watch for a major reduction in earnings & revenue. I would say in the neighbor of 30% to %40.AMAG will definitely tank to $10
Please quite the BS, no one is going to buy out ICPT for $400. Thanks God if you get $200
The arbitrage has been aggressively initiated in recent weeks,then there is going to blood among those arbitragers tomorrow morning.For the purpose of argument,lets assume that all 260 million of the increase in PFE short interest is merger related .That would also mean that arbs held long 23 million shares of AGN.At current prices that translates to loss of 372 million on PFE and 1.16 b on AGN from Fridays close.IF we also assume that %30 of this is option hedged,that translates into over 1 b in total losses..If the deal looks as if it is going to be unwound,a considerable % of the (%70 unhedged * 260m)182 million short position in PFE is going to cover over the near term and the same will hold true with (%70 unhedged*23m) 16 m shares of AGN will be sold .For the last 90 days average daily volume has been running at 42.2 m while AGN's has been 3.3m.Wall St traders who do not have positions in either will smell blood and will not be charitable in their offers and bids and will try to make it as painful as possible for those holding unhedged positions.
If you desire to go long AGN,it might be better to sell slightly out the money puts ,snce the volatility should explode.The same may apply to a lesser extent to PFE's calls
Type messageMr. Secretary, while I was preparing my remarks and my questions on cyber, I got a letter from your office to Senator Wyden and of course to the whole committee talking about inversion, which is something that everyone in this room cares about. You used the following language. You say that Congress should enact legislation immediately, make it retroactive to May 2014, to shut down this abuse of our tax system. I regard this as a ratchet up by your office to try to get this thing nipped in the bud. True?
JACOB LEW: We've made it clear for years that we want our tax codes to have incentives for investing in the United States and disincentives for taking business out of the United States.
On this question of inversion, I used language in my letter that's pretty strong and said we should have some economic patriotism here. It's not right to take an American firm and benefit from all the things that we do in the United States to make it a safe place to do business and then to say I don't want to pay taxes here, shift my corporate address overseas to pay a lower tax rate or no taxes.
What my letter says is the best way to deal with it is to do a comprehensive business tax reform. We have a plan out there that would accomplish multiple goals, as you and I have discussed, that we do business tax reform, lower our statutory business tax rate, provide resources to pay for infrastructure investments and fix the problem that is causing inversion.
In my letter yesterday, what I said was we cannot afford to wait, we need to send a signal that if we can't get comprehensive business tax reform done, we need to act on this question of inversion, that we need to do it now, and we need to do it retroactively so the businesses don't rush to do these transactions.
JIM CRAMER: But the other day, actually, July 14th, your Assistant Secretary for Legislative Affairs drafted a letter to Charles...basically saying, Look, the one thing you can't do is use the IRS, because...secure provision of 7874...will close a loophole. But why can't the IRS start some sort of rule making posture, which basically says to the general counsels out there, like Chris Cox and Cad...Waller, yes, you must do what you can to do an inversion right now?
Why can't you say, We're looking at the substantial interest provision. Because every one of the companies that are thinking about inverting right now is a mail drop, either in Switzerland or in Dublin. Just a mail drop. Nothing else. Many in the same building.
JACOB LEW: We have looked at the tax code. There are a lot of obscure provisions that we do not believe we have the authority to address this inversion question through administrative action. If we did, we would be doing more
Jun 14, 2016 4:20 PM EDT
June 14 (FlashRatings.com) - Analysts at Raymond James maintain their "outperform" rating for American Airlines Group, Inc. (AAL).
Funny, out perform rating. Define outperform ? Right now it's getting it #$%$ kick.
MS downgraded Intercept Pharmaceuticals from Equalweight to Underweight with a price target of $80 (prior $100). Cautious comments from analyst Andrew S Berens followed a favorable FDA panel vote supporting approval of Ocaliva in PBC. Berens believes concerns raised in the panel could impact the drug's label and eventual launch. He also thinks restrictions in cirrhotics could impact Ocaliva's potential in NASH.
"The panel unanimously recommended to approve the drug based on the surrogate endpoint used in the Phase 3 trial, but failed to endorse usage in advanced PBC patients given the lack of data supporting efficacy, as well as safety concerns," said Berens. "According to external consultants, the primary unmet medical need in this patient population is in patients with advanced or aggressive disease, so this lack of an endorsement by the panel has important commercial implications in our opinion, especially if the label is similarly restrictive."
The analyst continued, "The panel also expressed concerns about usage of the drug in patients with cirrhosis given the doserelated liver toxicity noted in the program. Additionally, the panel suggested that a less frequent dosing regimen be used in PBC patients with liver compromise and that patients be discontinued from treatment that do not respond within a specified time (6 or 12 months) given safety and tolerability concerns. We think these restrictions are likely to truncate the commercial PBC opportunity significantly and impact the launch, and therefore have lowered our peak PBC revenues to $117mn from $148mn."
Berens believes these concerns will weigh on ICPT shares ahead of the May 29 FDA action date, with potential for precautionary language in the drug's label.
Discussing NASH in more detail, the analyst said, "...The PBC panel clearly felt the drug was better suited for early stage liver disease without any hepatic compromise, which could be an issue in NASH if the same findings